Will Delcath Systems stock go up?

According to Danelfin AI, Delcath Systems has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.52%) is -4.29% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Delcath Systems stock?

The Delcath Systems target price is $22.31 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Delcath Systems stock right now?

Delcath Systems has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (46.52%) is -4.29% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Delcath Systems stock is a good buy .

Is Delcath Systems undervalued right now?

Based on analysts, the average price target upside for Delcath Systems is +72.57% (1Y). According to Danelfin AI, Delcath Systems has today an AI Score of 3/10 (Sell Rating).

What was the price range of Delcath Systems stock over the past 12 months?

The Delcath Systems stock price range over the past 12 months has been $8.19 - $14.16.

What is going on with Delcath Systems stock in the last 3 months?

The Delcath Systems stock performance in the last quarter has been +39.33%.

Does Delcath Systems offer dividend payments?

No, Delcath Systems does not currently pay dividends.

What is the current market capitalization of Delcath Systems?

Delcath Systems's market cap is $445.68M, as of 2026-07-02 08:00.

When is the next DCTH earnings report date?

DCTH will publish its next earnings report on 2026-05-07.

Delcath Systems Inc (DCTH) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

DCTH AI-Powered Stock Analysis

AI Score Explanation

AI Score

Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Delcath Systems Inc today receives an AI Score of 3/10, which translates to a Sell rating. The stock has a 48% probability of outperforming the market in the next 3 months, which is 3% lower than the average probability of any stock (51%). The top positive contributors include the long tail of fundamentals impact (+4.31%), long tail of technicals impact (+0.89%), and chart pattern (504d) (+0.72%). The top detractors are the Health Care Equipment & Supplies industry (-3.89%), plus directional indicator (90d) in the top 10% (-1.56%), chart pattern (120d) (-1.31%), operating profit margin in the bottom 40% (-0.99%), and fear & greed index at 31 (-0.99%). Notable data points include a gross margin of 85.05% in the top 20%, yet it detracts from probability (-0.74%), suggesting high margins are not currently rewarded. The plus directional indicator (90d) at 46.64 in the top 10% also detracts, indicating strong upward momentum may be overextended. Operating profit margin is deeply negative at -6.55% in the bottom 40%, weighing on the outlook. On the positive side, tangible shareholders' equity of $112.71M in the bottom 50% and alpha 1Y of -0.26 in the bottom 50% both contribute modestly. Overall, the stock faces headwinds from its industry, high volatility, and weak profitability, resulting in a below-average probability and a Sell rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+4.01%
How the stock is priced relative to its fundamentals
Earnings Quality+0.51%
Stability and reliability of reported earnings
Size & Liquidity+0.37%
Company size and trading liquidity

Sentiment-4.56%
How analysts and the market view the stock
Profitability-1.73%
Profitability and operating efficiency metrics
Momentum-1.47%
Direction and strength of recent price movements
Volatility-1.43%
How much the stock price tends to fluctuate

DCTH probability advantage of beating the market (3M):

-4.29%

AI Score

Sell

Delcath Systems (DCTH) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -4.29% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of DCTH (46.52%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
DCTH probability advantage of beating the market (3M)-4.29%
DCTH probability of beating the market (3M)46.52%

DCTH probability advantage of beating the market (3M): -4.29%

The AI-powered overall analysis of Delcath Systems (DCTH) is based on the 23 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of DCTH:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+4.31%
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-3.89%
Technical	Plus Directional Indicator (+DI, 90d)	46.64%		-1.56%
Technical	Chart Pattern (120d)	figure_144	N/A	-1.31%
Fundamental	Operating Profit Margin	-6.55%		-0.99%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.99%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.89%
Technical	Chart Pattern (180d)	figure_159	N/A	-0.87%
Fundamental	Gross Margin	85.05		-0.74%
Technical	Chart Pattern (504d)	figure_33	N/A	+0.72%
Technical	Upgrade to unlock			-0.67%
Technical	Upgrade to unlock			+0.65%
Fundamental	Upgrade to unlock			+0.64%
Sentiment	Upgrade to unlock			-0.61%
Technical	Upgrade to unlock			+0.53%

Rest of Alpha Signals: +0.76%

DCTH probability advantage of beating the market (3M)Total:-4.29%
DCTH AI Score

Significant changes Vs previous day

DCTH Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$12.93
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

DCTH Proven Sell Signal & Price Forecast

This is the price chart for DCTH from January 1, 2026 until today. The chart indicates, in red, the 58 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

DCTH Average Past Performance & Loss Rate

Three months after its 1513 Sell signals since July 2026, DCTH had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

1513 Past DCTH Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-38.73%
Average Alpha				-53.53%
Loss Rate (% Negative Perf.)				74.34%
% Negative Alpha				81.86%

DCTH Frequently Asked Questions

Will Delcath Systems stock go up?
According to Danelfin AI, Delcath Systems has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.52%) is -4.29% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Delcath Systems stock?
Is it a good time to buy, sell, or hold Delcath Systems stock right now?
Is Delcath Systems undervalued right now?
What was the price range of Delcath Systems stock over the past 12 months?
What is going on with Delcath Systems stock in the last 3 months?
Does Delcath Systems offer dividend payments?
What is the current market capitalization of Delcath Systems?
When is the next DCTH earnings report date?

Delcath Systems Inc Company Profile

Delcath Systems, Inc. is a specialized oncology organization that dedicates its resources to address primary and metastatic liver cancers in both the United States and Europe. The front-runner in Delcath's product lineup is the HEPZATO KIT, devised as a melphalan injection system that expertly targets chemotherapy treatment to the liver while simultaneously mitigating systemic exposure along with related side effects.

Underpinning this innovation, Delcath initiated the FOCUS clinical trial for HEPZATO, setting their sights on examining its objective response rate specifically geared toward patients bearing uveal melanoma with a hepatic dominance pattern.

In addition to this groundbreaking clinical candidate, Delcath also supplies HEPZATO purely as a medical device carrying the trade name CHEMOSAT Hepatic Delivery System. This equipment serves as an invaluable resource for European medical centers seeking effective solutions for a spectrum of liver cancers by leveraging Melphalan or CHEMOSAT therapy.

Dating back to 1988 when it first took shape, Delcath Systems, Inc. has established its operative base in New York, unfolding its groundbreaking work within this vibrant city.

Sector:
Country:United States
Industry:
Address:566 Queensbury Avenue, Queensbury
Employees:156
Website:delcath.com

Pros

Proprietary drug-device combination for targeted liver therapy

Orphan drug designation supporting market exclusivity

Specialized treatment addresses an unmet medical need

Established regulatory approval for US market access

Potential for premium pricing due to unique therapy

Cons

Limited patient population for the primary indication

Company	AI Score	Compare
AEMDAethlon Medical Inc

Company	AI Score	Compare
AEMDAethlon Medical Inc

DCTH Stock AI Analysis